IV Nutritional Therapies

iv nutritional therapies

Vitamin C

Integrative Medicine at The University of Kansas is a world leader in the area of IV vitamin C (IVC) treatment. IVC is vitamin C delivered directly into a patient’s bloodstream through a vein or port. It is used primarily as a complementary therapy for cancer patients, in combination with traditional cancer treatments such as chemotherapy.

Researchers at Integrative Medicine – including Jeanne Drisko, MD and Qi Chen, PhD – have been on the forefront of this therapy. In collaboration with researchers at the National Institutes of Health (NIH), Dr. Drisko and Dr. Chen have been researching IVC and its effects for more than a decade. Their findings include:
IVC is not for every cancer patient, but evidence has shown that for some patients, it can effectively augment conventional cancer treatment and improve quality of life for people undergoing conventional treatment. Our medical providers collaboratively decide if patients are appropriate for IVC, based on lab results and health histories, and with the support and coordination of patients’ oncology physicians.
infusion clinic

Other IV nutritional therapies

Vitamin and mineral therapies can also be helpful for people with other health problems whose digestive tracts are not properly absorbing nutrients, or who might need to replete nutrients quickly. These therapies, which also include IV magnesium and gluthatione, may be used after a comprehensive health or nutritional consultation with one of our healthcare providers.

Scientific research publications on IV vitamin C

  1. Levine, M. G. Espey, and Q. Chen, “Losing and finding a way at C: new promise for pharmacologic ascorbate in cancer treatment,” Free Radic. Biol. Med., vol. 47, no. 1, pp. 27–9, Jul. 2009.
  2. Chen, M. G. Espey, M. C. Krishna, J. B. Mitchell, C. P. Corpe, G. R. Buettner, E. Shacter, and M. Levine, “Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues.,” Proc. Natl. Acad. Sci. U. S. A., vol. 102, no. 38, pp. 13604–9, Sep. 2005.
  3. Chen, M. G. Espey, A. Y. Sun, J.-H. Lee, M. C. Krishna, E. Shacter, P. L. Choyke, C. Pooput, K. L. Kirk, G. R. Buettner, and M. Levine, “Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo.,” Proc. Natl. Acad. Sci. U. S. A., vol. 104, no. 21, pp. 8749–54, May 2007.
  4. iv therapies nurse
  5. Chen, M. G. Espey, A. Y. Sun, C. Pooput, K. L. Kirk, M. C. Krishna, D. B. Khosh, J. Drisko, and M. Levine, “Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice.,” Proc. Natl. Acad. Sci. U. S. A., vol. 105, no. 32, pp. 11105–9, Aug. 2008.
  6. J. Padayatty, A. Y. Sun, Q. Chen, M. G. Espey, J. Drisko, and M. Levine, “Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects.,” PLoS One, vol. 5, no. 7, p. e11414, Jan. 2010.
  7. Ma, J. Chapman, M. Levine, K. Polireddy, J. Drisko, and Q. Chen, “High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy.,” Sci. Transl. Med., vol. 6, no. 222, p. 222ra18, Feb. 2014.
  8. G. Espey, P. Chen, B. Chalmers, J. Drisko, A. Y. Sun, M. Levine, and Q. Chen, “Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer,” Free Radic. Biol. Med., vol. 50, no. 11, pp. 1610–1619, 2011.
  9. Ma Y, Sullivan GG, Schrick E, Choi IY, He Z, Lierman J, Drisko J, Chen Q. “A convenient method for measurement of blood ascorbate concentrations in patients receiving high-dose intravenous ascorbate.,” J Am Coll Nutr 2013, 32(3): 187-93.
  10. Chen P, Stone J, Sullivan G, Drisko J, Chen Q. “Supplementary glutathione counteracts with pharmacologic ascorbate in pre-clinical cancer models,” Free Radic Biol Med. 2011,51:681-687.